Generic Name: Eldepryl
What is Eldepryl?
This is typical of the interaction of meperidine and MAOIs. Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin re-uptake inhibitors and ELDEPRYL. One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication ephedrine.
Selegiline did not induce mutations or chromosomal damage when tested in the bacterial mutation assay in Salmonella typhimurium and in an in vivo chromosomal aberration assay. While these studies provide some reassurance that selegiline is not mutagenic or clastogenic, they are not definitive because of methodological limitations.
No definitive in vitro chromosomal aberration or in vitro mammalian gene mutation assays have been performed. In the rat study, there was a decrease in fetal body weight at the highest dose tested.
There are no adequate and well-controlled studies in pregnant women. Selegiline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether selegiline hydrochloride is excreted in human milk.
Because many drugs are excreted in human milk, consideration should be given to discontinuing the use of all but absolutely essential drug treatments in nursing women.
Dizziness, abdominal pain, dry mouth, nausea, stomach upset, trouble sleeping, and headache may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. If you are also taking levodopa, you may experience more side effects from the levodopa when taking selegiline. Your doctor may need to change your medication or dose.
Do not stop or change the dose of your levodopa without talking with your doctor first. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects.
Many people using this medication do not have serious side effects. Some people taking selegiline have fallen asleep suddenly during their usual daily activities such as talking on the phone, driving. In some cases, sleep occurred without any feelings of drowsiness beforehand.
This sleep effect may occur anytime during treatment with selegiline even if you have used this medication for a long time. If you experience increased sleepiness or fall asleep during the day, do not drive or take part in other possibly dangerous activities until you have discussed this effect with your doctor.
Your risk of this sleep effect is increased by using alcohol or other medications that can make you drowsy. See also Precautions section. This drug may rarely cause an attack of extremely high blood pressure hypertensive crisiswhich may be fatal. Many drug and food interactions can increase this risk.
How should I take Eldepryl?
It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged. Text only version for the visually impairedBelow is a text only representation of the Patient Information leaflet. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. What Eldepryl is and what it is used for 2.
What you need to know before you take Eldepryl 3. Contents of the pack and other informationEldepryl is available as a 5 mg and 10 mg Tablet. Eldepryl contains the active substance selegiline hydrochloride.
What should I avoid while taking Eldepryl?
Levobetaxolol: Additive hypotensive effects may be seen when monoamine oxidase inhibitors MAOIs are combined with antihypertensives. Levobunolol: Additive hypotensive effects may be seen when monoamine oxidase inhibitors MAOIs are combined with antihypertensives. Levodopa: Concurrent therapy with MAO-B inhibitors and levodopa may be associated with severe orthostatic hypotension not attributable to levodopa alone.
Levomethadyl: Concomitant use of central nervous system depressants, such as MAOIs, can potentiate the effects of levomethadyl, which may potentially lead to respiratory depression, CNS depression, sedation, or hypotensive responses.
Levomilnacipran: Due to the risk of serotonin syndrome, monoamine oxidase inhibitors MAOIs intended to treat psychiatric disorders are contraindicated for use with serotonin norepinephrine reuptake inhibitors SNRIs. Levorphanol: Levorphanol is specifically not recommended for use with monoamine oxidase inhibitors MAOIs due to possible additive CNS depressant effects. Linagliptin: Animal data indicate that monoamine oxidase inhibitors MAOIs may stimulate insulin secretion.
Eldepryl side effects
Under steady-state conditions, the median elimination half-life increases to 10 hours. Selegiline ODT produces a smaller fraction of the administered dose recoverable as the metabolites than the conventional swallowed formulation of selegiline.
Additionally, substantially lower metabolite L-desmethylselegiline, L-amphetamine, L-methamphetamine concentrations are seen, compared to oral dosing. Steady-state plasma concentrations are achieved within 5 days. Transdermal selegiline does not accumulate in and is not metabolized in the skin and does not undergo extensive first-pass metabolism. In one study, steady-state selegiline plasma concentrations indicated selegiline concentration-time profiles were comparable when transdermal selegiline is applied to the upper torso or upper thigh, and absorption from these two sites of administration was equivalent.
Selegiline prevents the breakdown of a chemical in your brain called dopamine DO pa meen. Low levels of this chemical are associated with Parkinson's disease.
Common Eldepryl ide effects may include:
Reassessment for oversedation is suggested throughout therapy.
Olmesartan: Additive hypotensive effects may be seen when selegiline is combined with angiotensin II receptor antagonists.
Because rasagiline is a selective monoamine oxidase-B MAO-B inhibitor at manufacturer recommended doses, an interaction with serotonin-enhancing medications may be less likely to occur than with other traditional MAO inhibitors.
Thiopental: Patients receiving MAOIs may have an increased risk of hypotension after administration of general anesthetics.
Like phenelzine, the effects of selegiline are cumulative, with beneficial effects seen in a few days to several months depending on the condition being treated and individual response. Orally Disintegrating Tablet ODT : Following administration of the orally disintegrating tablet, disintegration and absorption occur rapidly. Detectable levels of selegiline from selegiline ODT have been measured 5 minutes after administration.
Where can I get more information?
At that point, selegiline is added.
Dose adjustments may be required.